[Comments on the Ito et al. article (Endocr J. 2008 Oct 8. Epub ahead of print)] the lack of clinicopathological correlation of BRAF mutation in papillary thyroid cancer needs to be interpreted with caution

Endocrine Journal

Volumn 56, Issue 2, 2009, Pages 305-306

  Xing, Mingzhao ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; RADIOACTIVE IODINE;

CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CLINICAL FEATURE; DISTANT METASTASIS; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LETTER; LYMPH NODE METASTASIS; PAPILLARY CARCINOMA; RADIOISOTOPE THERAPY; THYROID CANCER; TREATMENT RESPONSE;

CARCINOMA, PAPILLARY; DISEASE-FREE SURVIVAL; HUMANS; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 66849119254     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K08E-335     Document Type: Letter

References (4)

1. Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, Kihara M, Uruno T, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A (2009) BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-rree survival of patients. Endocr J 56: 89-97.
2. Xing M (2007) BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28: 742-762.
3. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S (2003) Clinical implication of hot spot BRAF mutation, V599E, in papillary thy-roid cancers. J Clin Endocrinol Metab 88: 4393-4397.
4. Nakayama H, Yoshida A, Nakamura Y, Hayashi H, Miyagi Y, Wada N, Rino Y, Masuda M, Imada T (2007) Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. Anticancer Res 27: 3645-3649.